The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
Since the publication of these guidelines in 2016, PDE4i and IL-17i agents have been approved for the treatment of PsA
GRAPPA recommendations highlight the need to determine treatment based in part on the domains involved in PsA and drug interactions that can compromise the management of comorbidities1
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) is a global network of rheumatologists and dermatologists who have provided evidence-based guidance for the treatment and management of adult patients with psoriatic arthritis.1
On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.
For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.